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Abstract
Background: Health-related quality of life (HRQoL) in adolescents and young adults with bleeding disorders
is under-researched. We aimed to describe factors related to HRQoL in adolescents and young adults with
hemophilia A or B or von Willebrand disease.
Methods: A convenience sample of volunteers aged 13 to 25 years with hemophilia or von Willebrand
disease completed a cross-sectional survey that assessed Physical (PCS) and Mental (MCS) Component
Summary scores on the SF-36 questionnaire. Quantile regression models were used to assess factors
associated with HRQoL.
Results: Of 108 respondents, 79, 7, and 14% had hemophilia A, hemophilia B, and von Willebrand disease, respectively.
Most had severe disease (71%), had never developed an inhibitor (65%), and were treated prophylactically (68%). Half of
patients were aged 13 to 17 years and most were white (80%) and non-Hispanic (89%). Chronic pain was reported as
moderate to severe by 31% of respondents. Median PCS and MCS were 81.3 and 75.5, respectively. Quantile regression
showed that the median PCS for women (61% with von Willebrand disease) was 13.1 (95% CI: 2.4, 23.8; p = 0.02) points
lower than men. Ever developing an inhibitor (vs never) was associated with a 13.1-point (95% CI: 4.7, 21.5; p < 0.01) PCS
reduction. MCS was 10.0 points (95% CI: 0.7, 19.3; p = 0.04) higher for prophylactic infusers versus those using
on-demand treatment. Compared with patients with no to mild chronic pain, those with moderate to severe
chronic pain had 25.5-point (95% CI: 17.2, 33.8; p < 0.001) and 10.0-point (95% CI: 0.8, 19.2; p = 0.03) reductions
in median PCS and MCS, respectively.
Conclusions: Efforts should be made to prevent and manage chronic pain, which was strongly related to
physical and mental HRQoL, in adolescents and young adults with hemophilia and von Willebrand disease.
Previous research suggests that better clotting factor adherence may be associated with less chronic pain.
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Background
Therapeutic advancements [1–4], improved treatment
approaches [5–8], and enhanced care delivery models
[9–12] have resulted in highly active lifestyles and near-
normal life expectancy for persons diagnosed with a
bleeding disorder [13]. As treatments continue to im-
prove, patient care will continue to evolve toward pre-
venting bleeding disorder complications, such as
hemophilic arthropathy, chronic pain, and inhibitor
development—with the ultimate goal of attaining and
maintaining high health-related quality of life (HRQoL)
for those affected by the disorder [14]. Previous research
has shown that among persons with a bleeding disorder,
HRQoL may be related to pain, treatment type (prophy-
laxis vs on-demand), adherence, age-related concerns,
inhibitor status, or depression [14–21]. These findings
suggest that bleeding disorders particularly diminish the
physical aspects of HRQoL and that alleviating the clin-
ical burden of bleeding disorders may be particularly
important for improving and maintaining physical well-
being and overall HRQoL.
Measuring HRQoL is a unique way to assess the gen-
eral well-being and perceived health of individuals living
with a bleeding disorder, the experiences related to hav-
ing a bleeding disorder, and satisfaction with treatment
[22]. However, very little, if any, data exist that describe
HRQoL among adolescent and young adult (AYA) per-
sons diagnosed with a bleeding disorder. AYAs are a
unique population of bleeding disorder patients who are
often just starting to take more responsibility for the
management of their own disease and developing treat-
ment habits that can carry over into adult life [23]. En-
tering adolescence and young adulthood might mean
finally confronting the demands that managing a bleed-
ing disorder entails. The aim of this study was to investi-
gate the relationships between pain management,
adherence to prescribed treatment, and HRQoL in AYA
persons with hemophilia (PWH) or von Willebrand dis-
ease (VWD).
Methods
Study population and recruitment
Data describing HRQoL, adherence to prescribed treat-
ment regimens, and level of chronic pain among AYA
PWH or VWD were obtained as part of the larger Inter-
relationship Between Management of Pain, Adherence to
Clotting-factor Treatment, and Quality of Life (IMPACT
QoL) study. As the name suggests, the IMPACT QoL
study had the primary goal of assessing the relationship
between validated measures of pain, clotting-factor adher-
ence, and HRQoL among AYA PWH or VWD. Data
describing the relationship between adherence to a pre-
scribed clotting factor treatment regimen and chronic
pain, along with racial differences in chronic pain and
QoL from this study, were previously reported [24, 25].
Data were collected via a one-time, cross-sectional, online
survey from a convenience sample of AYA PWH or
VWD. To be eligible to complete the survey, participants
had to be aged 13 to 25 years, read, write, and speak
English, and have hemophilia A, hemophilia B, or VWD.
Recruitment occurred at major US hemophilia meetings
(e.g., Inhibitor Summits and National Hemophilia Foun-
dation meetings), US hemophilia treatment centers, and
through a Facebook© page dedicated to the study from
April through December of 2012. All surveys were com-
pleted electronically using SurveyMonkey® and Apple®
iPads®. Informed consent was obtained from all individual
participants included in the study. The study was ap-
proved by the Munson Medical Center (Traverse City,
MI) institutional review board prior to data collection. All
data were de-identified prior to analysis. The current
study uses the IMPACT QoL survey data to determine
factors associated with better HRQoL among AYA (aged
13–25 years) PWH or VWD.
Measurement
HRQoL was measured using the 36-Item Short Form
Health Survey (SF-36). The SF-36 is composed of 8
multi-item scales (35 items) assessing the following: (1)
bodily pain (BP, 2 items), (2) physical function (PF, 10
items), (3) role limitations due to physical health prob-
lems (RP, 4 items), (4) general health (GH, 5 items), (5)
vitality (VT, 4 items), (6) social functioning (SF, 2 items),
and (7) role limitations due to emotional problems (RE,
3 items) and emotional well-being/mental health (MH, 5
items) [26]. The 36th item, which asks about health
change, is not included in the scale or summary scores.
Each subscale is calculated by taking the average of the
participant’s responses to the questions contained in the
subscale and then standardizing it so that each had a
final range of 0 (lowest level of functioning) to 100
(highest level of functioning). These eight scales can be
aggregated into two summary measures: the Physical
(PCS) and Mental (MCS) Component Summary scores,
where higher scores represent better health. The scoring
algorithm for PCS includes positive weights for the PF,
RP, BP, GH, and VT scales and negative weights for the
SF, RE, and MH. The scoring algorithm for MCS in-
cludes positive weights for the VT, SF, RE, and MH
scales and negative weights for the PF, RP, BP, and GH
scales. Three scales (PF, RP, and BP) correlate most
highly with the physical component and contribute most
to the scoring of the PCS. The MCS correlates most
highly with the MH, RE, and SF scales, which also con-
tribute most to the scoring of the MCS measure. Three
of the scales (VT, GH, and SF) have noteworthy correla-
tions with both components. The SF-36 was constructed
for self-administration by persons 14 years of age and
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older, and for administration by a trained interviewer in
person or by telephone [26].
Adherence was assessed using the Validated
Hemophilia Regimen Treatment Adherence Scale (VER-
ITAS)-Pro [27] and VERITAS-PRN [28] for prophylactic
and on-demand (i.e., episodic) participants, respectively.
VERITAS scores range from 24 (most adherent) to 120
(least adherent). As an experimental measure, we also
combined VERITAS-Pro and VERITAS-PRN responses
into one category (VERITAS-combined) [25] to evaluate
the relationship between adherence and HRQoL for both
prophylactic and on-demand AYA PWH simultaneously.
The cutoff for non-adherent prophylactic participants
was a total VERITAS-Pro score ≥57 as previously estab-
lished [27]. The cutoff for non-adherent on-demand
patients has not been previously described and was de-
fined as those with VERITAS-PRN in the highest quar-
tile of all responses. This value was chosen because the
VERITAS-Pro cutoff was approximately the 75th per-
centile of all responses.
Chronic pain was measured using the revised Faces
Pain Scale-Revised (FPS-R). The FPS-R is a visual scale
composed of six faces illustrating an increasing level of
pain intensity. Respondents were asked to choose the
face that best describes the intensity of the chronic pain
they experienced. In the IMPACT HRQoL survey,
chronic pain was defined as ‘pain that you have every
day or almost every day, and that always or almost al-
ways seems to be there even when you are not having a
bleed at that moment.’ FPS-R scores range from 0 to 10
with the faces representing the lowest and highest
levels of pain intensity coded as 0 and 10, respect-
ively. The FPS-R is highly correlated with the visual
analog scale (r = .93) and with the colored analog
scale (r = .84), demonstrating strong validity. Reliabil-
ity and validity of the FPS-R have been established
for a broad age range, ranging from children as young
as 4 years old to adults [29]. For purpose of analysis,
chronic pain was dichotomized as high for those who
reported their pain as ‘moderate,’ ‘severe,’ ‘very severe,’
or ‘worst pain possible’ (i.e., FPS-R ≥4) and low for
‘mild pain’ or ‘no pain’ (i.e., FPS-R <4).
Other self-reported data collected included informa-
tion about participant age, gender, race, ethnicity, health
insurance status/type, and the educational level of the
participants’ parents. Data were also collected about
bleeding disorder type (hemophilia A or B, or VWD),
whether or not the participant ever developed an inhibi-
tor to treatment, and bleeding disorder severity. For
hemophilia A and B, severity was classified as mild,
moderate, or severe corresponding to 6 to 50%, 1 to 5%,
and <1%, respectively, of the normal amount of clotting
factor. VWD was classified as mild, moderate, or severe
corresponding to Type I (lower than normal levels of
von Willebrand factor), Type II (lower than normal
levels and improper functioning of von Willebrand fac-
tor), and Type III disease (absence of von Willebrand
factor in the blood).
Statistical analysis
Because of their skewed nature, descriptive statistics and
univariate relationships were assessed by tabulating me-
dian PCS and MCS SF-36 scores with interquartile
ranges (IQRs) by participant sociodemographic and clin-
ical characteristics. Percentages were used to describe
categorical variables and statistical association with SF-
36 scores was assessed using the non-parametric
Wilcoxon rank sum test or Kruskal Wallis test (depend-
ing on degrees of freedom), as they do not assume a
normal distribution of the residuals. As part of an ex-
ploratory analysis, we also examined univariate rela-
tionships between participant sociodemographic and
clinical characteristics and each of the eight SF-36
subscales. Because this portion of the analysis was
only exploratory, no adjustments for multiple compar-
isons were made.
The primary outcome variables of interest (SF-36
PCS and MCS scores) were largely skewed, thus mul-
tivariable, quantile regression models were used to as-
sess factors associated with physical and emotional
SF-36 subscales. Factors assessed for their relationship
with HRQoL included: age, gender, race and ethnicity,
parent’s education level, bleeding disorder type and
severity, history of inhibitor development, level of
chronic pain, clotting-factor treatment adherence, and
treatment regimen type (on-demand vs prophylactic).
Due to the large number of variables collected as part
of the survey and because of the small sample size in-
herent in rare disease research, in addition to the
fully adjusted models, final parsimonious models were
constructed. In the final parsimonious models, we de-
cided, a priori, to include covariates in the model
only if they (1) were statistically significant at a two-
tailed alpha level of .05, (2) changed the coefficient of
another statistically significant model parameter by at
least 10% to 15% (i.e., confounded) [30], or (3) im-
proved the precision of another statistically significant
parameter already in the model. All statistical analyses
were performed using SAS 9.2 (SAS Institute, Inc;
Cary, NC). All p-values were calculated using two-
sided tests.
Results
Respondent characteristics are summarized in Table 1.
Overall, 108 AYAs with hemophilia A, hemophilia B,
and VWD participated; half of the participants were
aged 13 to 17 years, and the majority were male (83%).
Male participants were more likely to have hemophilia
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vs VWD (96 vs 4%), while the opposite was true for
female participants (39 vs 61%). The majority (94%) of
respondents had some type of health insurance.
Median PCS and MCS were 81.3 (IQR: 61.1–93.1;
range: 12.9–100) and 75.5 (IQR: 60.0–84.3.1; range:
27.1–100), respectively (Figs. 1 and 2). Mean values for
PCS, MCS, and the eight multi-item subscales were gen-
erally lower than the median (with the exception of VT
and SF) due to low outlying values (Fig. 3). At the uni-
variate level, young adults (vs adolescents), non-whites,
those who reported ever developing an inhibitor, and
those who reported moderate to severe (vs none to mild)
chronic pain had statistically significantly lower PCS
scores (Table 2). Young adults (vs adolescents), those
who reported moderate to severe (vs none to mild)
chronic pain, and those who were non-adherent to
prescribed clotting-factor treatment regimens had sta-
tistically significantly lower MCS scores (Table 2).
Univariate level differences for PCS, MCS, and the















Medicaid or VA onlyc 34 32
Commercial only 46 43
Both 8 7
Insured – type unknown 12 11
Uninsured 6 6
Mother’s education level
Bachelor’s degree or higher 38 35
Less than Bachelor’s degree 70 65
Father’s education level
Bachelor’s degree or higher 31 29
Less than Bachelor’s degree 71 71
Bleeding disorder
Hemophilia A 85 79
Hemophilia B 5 7












None to mild 74 69
Moderate to severe 34 31




aMost (73%) of non-white respondents were black or African American, 14%
were mixed race, 9% were Asian, and 5% were American Indian or
Alaskan Native
bn = 78, two respondents answered ‘Don’t know’ as to whether or not they
had health insurance, and were not included
cOnly two respondents had VA only insurance, the others had Medicaid only
dChronic pain was measured using the revised Faces Pain Scale (FPS-R) and
was dichotomized as FPS-R < 4 (i.e., ‘mild’ or ‘no pain) and FPS-R ≥4
(ie, ‘moderate’ to ‘worst pain possible’)
eAdherence was assessed using the Validated Hemophilia Regimen Treatment
Adherence Scale (VERITAS)-Pro and VERITAS-PRN for prophylactic and on-demand
participants, respectively. The cutoff for non-adherent prophylactic participants
was a total VERITAS-Pro score ≥57 as established in previously by Duncan and
colleagues [25]. This value was chosen because the VERITAS-Pro cutoff was
approximately the 75th percentile of all responses
Fig. 1 Distribution of SF-36 Physical Component Summary scores
(n = 108). SF-36, 36-Item Short Form Health Survey; PCS, Physical
Component Summary
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eight multi-item subscales by respondent characteristic
are shown in the supplement (Figs 4 and 5 for median and
mean values, respectively).
Final quantile regression models suggested that,
compared with men, median PCS for women was
13.1 (95% CI: 2.4, 23.8; p = 0.02) points lower. Ever
developing an inhibitor (vs never) was significantly
associated with a 13.1 (95% CI: 4.7, 21.5; p < 0.01)
point reduction in PCS. Prophylactic infusers (vs on-
demand) had a 10.0 (95% CI: 0.7, 19.3; p = 0.04) point
increase in median MCS. Compared with those with
no or mild chronic pain, those with moderate to severe
chronic pain had a 25.5 (95% CI: 17.2, 33.8; p < 0.001) and
10.0 (95% CI: 0.8, 19.2; p = 0.03) point reduction in
median PCS and MCS, respectively. Tables 3 and 4 show
final quantile regression models modeling PCS and MCS
scores, respectively.
Discussion
Evaluating HRQoL will be required to determine the
effectiveness of care strategies and to measure the im-
pact of living with a bleeding disorder over time. To our
knowledge, limited data are available regarding the
HRQoL of AYAs with hemophilia. In contrast to previ-
ous surveys, such as Hemophilia Experiences, Results
and Opportunities (HERO), that assessed psychosocial
issues in PWH [31–33], we assessed adherence using the
validated VERITAS scale and used the SF-36 (vs the
EuroQoL-5 dimensions [EQ-5D]) to assess HRQoL. The
SF-36 assesses domains such as vitality and social func-
tioning, which are not included in the EQ-5D [34].
Additionally, all patients in our study self-reported for
assessments of QoL, whereas parents responded on be-
half of children younger than 18 years in HERO [32].
Consistent with previous research in PWH among other
age groups [35], AYA PWH or VWD who reported they
had ever developed an inhibitor and those who reported
moderate-to-severe chronic pain also reported worse
physical HRQoL in this study. Previous reports suggest
this finding is likely explained by the fact that most
PWH report that pain interferes with daily activities
and has a negative impact on their work. In addition
to physical limitations in daily activity and work,
prior research has suggested an emotional impact of
chronic pain on quality of life as well [36, 37].
Witkop et al. demonstrated that one third of PWH
report that pain impairs the ability to form close rela-
tionships and that nearly half of young adults with a
bleeding disorder report being diagnosed with anxiety
or depression [37]. It has been suggested that, in
addition to emphasizing prophylaxis, interventions to
promote acceptance of pain and to reduce negative
thoughts about pain should be utilized when ap-
proaching PWH [15].
Adolescents had higher PCS and MCS scores com-
pared to young adults, which may be related to more
frequent disease-related bleeding and greater prevalence
of chronic pain as individuals managing a bleeding
disorder transition from adolescence to young adult-
hood. Previous research has underscored that adherence
to treatment regimens declines with age. Diligent factor
administration by parents in younger years often gives
way to less treatment regimen fidelity during young
adulthood where patients often begin to assume pri-
mary responsibility for their bleeding disorder care
[22, 23, 38, 39]. Further, as children transition into
young adulthood, their activity level often intensifies,
which could heighten the risk of bleeding.
Fig. 2 Distribution of SF-36 Mental Component Summary scores
(n = 108). SF-36, 36-Item Short Form Health Survey; MCS, Mental
Component Summary
Fig. 3 Box plots for SF-36 component and subscale scores (n = 108).
The solid white line represents median value, and the white
diamond represents the mean value. PCS, Physical Component
Summary score; MCS, Mental Component Summary; BP, bodily
pain; PF, physical function; RP, role limitations due to physical
health problems; GH, general health; VT, vitality; SF, social functioning;
RE, role limitations due to emotional problems; MH, emotional
well-being/mental health
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Table 2 Median (IQR) SF-36 Physical and Mental Component Summary scores by respondent characteristic (n = 108)
Characteristic SF-36 PCS p-value SF-36 MCS p-value
Age 0.03 0.04
13–17 86.3 (64.8, 95.7) 79.5 (64.6, 85.7)
18–25 75.1 (59.0, 87.1) 73.4 (58.6, 78.9)
Gender 0.12 0.10
Male 83.0 (59.0, 94.5) 76.8 (59.6, 85.7)
Female 78.9 (64.8, 86.0) 71.4 (64.6, 76.4)
Race 0.02 0.94
White 83.6 (65.7, 94.3) 75.9 (59.6, 84.3)
Non-whitea 62.6 (48.3, 84.8) 74.3 (64.6, 85.7)
Ethnicity 0.18 0.73
Hispanic 71.9 (59.3, 81.5) 77.0 (67.0, 82.1)
Non-Hispanic 83.0 (61.1, 94.2) 75.2 (59.6, 84.8)
Health insuranceb 0.13 0.21
Medicaid or VA onlyc 79.4 (56.0, 86.4) 75.9 (64.6, 85.7)
Commercial only 86.2 (65.0, 95.7) 78.8 (65.0, 84.3)
Both 71.0 (60.8, 77.7) 72.9 (59.3, 81.3)
Insured, type unknown 83.7 (69.6, 91.8) 64.3 (54.6, 86.3)
Uninsured 63.0 (41.4, 90.5) 61.8 (42.9, 69/3)
Mother’s education level 0.19 0.71
Bachelor’s degree or higher 86.1 (65.7, 95.5) 75.7 (60.4, 85.4)
Less than Bachelor’s degree 80.1 (58.1, 91.0) 75.5 (59.6, 84.3)
Father’s education level 0.10 0.46
Bachelor’s degree or higher 88.3 (67.4, 95.5) 76.4 (58.6, 87.1)
Less than Bachelor’s degree 79.8 (58.1, 91.0) 75.4 (60.4, 82.9)
Bleeding disorder 0.78 0.34
Hemophilia A 81.2 (58.1, 94.5) 76.4 (59.3, 85.7)
Hemophilia B 81.7 (73.2, 88.5) 76.1 (65.0, 81.8)
von Willebrand 80.5 (64.8, 86.2) 70.0 (64.6, 76.4)
Severity 0.98 0.37
Mild 81.6 (65.0, 91.7) 73.2 (61.8, 78.6)
Moderate 86.0 (64.0, 88.6) 75.4 (60.4, 87.1)
Severe 79.8 (58.1, 94.3) 76.4 (59.6, 85.7)
Inhibitor development <0.01 0.16
Ever 69.0 (45.0, 85.2) 73.4 (56.8, 83.9)
Never 86.1 (67.9, 94.5) 78.2 (64.6, 86.4)
Treatment regimen 0.99 0.13
On-demand 81.9 (66.2, 91.7) 72.9 (59.3, 78.9)
Prophylaxis 81.2 (58.1, 94.5) 77.1 (60.4, 85.7)
Chronic paind <0.0001 0.01
None to mild 87.1 (75.5, 95.5) 77.1 (64.6, 86.8)
Moderate to severe 59.0 (45.0, 74.5) 72.9 (56.8, 78.8)
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AYA females with a bleeding disorder reported
lower physical HRQoL when compared with AYA
men in this study, even after adjustment for other
sociodemographic and clinical factors. Reasons for
this are not clear. Previous work would suggest the
opposite might be true given that, compared with
AYA males, female AYA were more likely to have
VWD (vs hemophilia) and that VWD, generally
speaking, has a lower overall burden of disease than
does hemophilia and is less commonly associated with
the cumulative arthropathic burden in adulthood
often seen in PWH [40]. However, approximately one
in four patients with VWD experience joint bleeds,
which can have a negative effect on physical quality
of life, with the majority of first joint bleeds occurring
before age 16 [40]. In addition, previous research has
suggested that physical quality of life in female VWD
patients may be affected by menorrhagia, dysmenor-
rhagia, or pregnancy-related bleeding, which could
lead to anemia, fatigue, and pain [41–43]. Thus, in
AYA, it is possible that acute bleeding and dysmenor-
rhea often associated with female VWD patients have
a more immediate deleterious effect on HRQoL than
do the long-term effects (e.g., arthropathy and hepa-
titis C) associated with hemophilia which may have
not yet fully manifested. This interaction between age,
sex, bleeding disorder type, and HRQoL should be
more thoroughly evaluated with future research.
AYA patients who infused clotting factor prophylac-
tically reported significantly better mental HRQoL
(MCS) compared with those who infused using on-
demand regimens. However, differences in physical
HRQoL (PCS) were not observed in our study, which
is a surprising finding given that prophylaxis is asso-
ciated with fewer joint bleeds and less pain [7], and a
recent review found that joint status was associated
with both social and emotional well-being [44]. One
possible explanation for the findings in our study is
that physical sequelae of the disease have not yet
manifested in AYAs, a hypothesis also set forth by
Poon et al. [20]. However, prophylactic treatment may
provide mental assurance to patients that their dis-
ease is well controlled, thereby leading to improved
mental HRQoL. Future studies should attempt to
tease out the influence of prophylaxis, disease type
and severity, and comorbid illness on HRQoL.
This study has limitations. Primarily, data are cross-
sectional, thus causal inference cannot be made.
Specifically, although study results support that sev-
eral factors (e.g., chronic pain, inhibitor development,
clotting-factor regimen type) are related to HRQoL,
Table 2 Median (IQR) SF-36 Physical and Mental Component Summary scores by respondent characteristic (n = 108) (Continued)
Clotting factor adherencee 0.24 0.04
Adherent 82.6 (64.8, 95.5) 76.4 (64.6, 84.3)
Non-adherent 79.0 (55.5, 90.5) 68.2 (48.6, 78.6)
aMost (73%) of non-white respondents were black or African American, 14% were mixed race, 9% were Asian, and 5% were American Indian or Alaskan Native
bn = 78, two participants answered ‘Don’t Know’ to whether or not they had health insurance and were not included
cOnly two participants had VA only insurance, the others had Medicaid only
dChronic Pain was measured using the revised Faces Pain Scale (FPS-R) and was dichotomized as FPS-R < 4 (i.e., ‘mild’ or ‘no pain) and FPS-R ≥ 4 (i.e., ‘moderate’
to ‘worst pain possible’)
eAdherence was assessed using the Validated Hemophilia Regimen Treatment Adherence Scale (VERITAS)-Pro and VERITAS-PRN for prophylactic and on-demand
participants, respectively. The cutoff for non-adherent prophylactic participants was a total VERITAS-Pro score ≥57, as established previously by Duncan and
colleagues [25]. This value was chosen because the VERITAS-Pro cutoff was approximately the 75th percentile of all responses
SF-36 36-Item Short Form Health Survey, MCS Mental Component Summary, PCS Physical Component Summary
Table 3 Quantile (median) regression model estimating median
SF-36 Physical Component Summary scores, 2012 (n = 108)
Characteristic Coefficient (95% CI) p-value
Gender 0.02
Female −13.1 (−23.8, −2.4)
Male reference
Inhibitor development <0.01
Ever −13.1 (−21.5, −4.7)
Never reference
Chronic paina <0.001
Moderate to severe −25.5 (−33.8, −17.2)
None to mild reference
aChronic pain was measured using the revised Faces Pain Scale (FPS-R) and
was dichotomized as FPS-R <4 (i.e., ‘mild’ or ‘no pain) and FPS-R ≥4 (i.e., ‘mod-
erate’ to ‘worst pain possible’)
Table 4 Quantile (median) regression model estimating median
SF-36 Mental Component Summary scores, 2012 (n = 108)a
Characteristic Coefficient (95% CI) p-value
Treatment regimen 0.04
Prophylaxis 10.0 (0.7, 19.3)
On-demand reference
Chronic painb 0.03
Moderate to severe −10.0 (−19.2, −0.8)
None to mild reference
aEthnicity (Hispanic vs non-Hispanic) and history of inhibitor development
(ever vs never) were also included in the model, though not statistically
significant, because they increased the precision of the estimates
bChronic pain was measured using the revised Faces Pain Scale (FPS-R) and
was dichotomized as FPS-R < 4 (i.e., ‘mild’ or ‘no pain) and FPS-R ≥ 4
(i.e., ‘moderate’ to ‘worst pain possible’)
CI confidence interval
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the directionality of this relationship cannot be con-
firmed. That is, though we modeled how these factors
affect HRQoL, it is also possible that HRQoL instead
affects a patient’s willingness and ability to adequately
manage his or her bleeding disorder. This cannot be
teased out in a cross-sectional study and should be
examined in the future with prospective studies. A
second limitation is that all data are self-reported. As
such, information about blood disorder type and se-
verity, health insurance coverage, and other demo-
graphic, clinical, and behavioral factors are not
confirmed by medical record review or administrative
claims data. However, by obtaining data through self-
report, this study was able to collect important, reli-
able, and valid patient-report outcomes (PRO) data
about adherence, chronic pain, and HRQoL. Patient-
reported data about pain and HRQoL are considered
the ‘gold standard,’ and the VERITAS scales are the
only validated measures of adherence to clotting-
factor treatment developed to date.
Another limitation is that the VERITAS-combined
score that we reported, though statistically comprised of
two validated instruments, is an experimental, non-
validated measure that has only been previously reported
once [25]. Most participants (68%), however, treated
prophylactically, and VERITAS-Pro scores, which have
been previously validated, confirmed the results of the
experimental, combined score. Additionally, the SF-
36, used in this study to assess HRQoL, is only vali-
dated in persons aged 14 years and older [26],
whereas a small percentage of patients in our study
were aged 13 years (n = 9/108, 8.3%). Further, no
comparisons were made between SF-36 results in
study respondents versus matched normal controls or
persons living with other chronic diseases. Finally,
AYA PWH and VWD were primarily recruited from
large national or regional hemophilia meetings. Thus,
our convenience sample of AYA PWH and VWD may
not adequately represent the broader AYA PWH and
VWD population who do not typically attend these
meetings.
Conclusions
Efforts should be made to prevent and manage chronic
pain, which was strongly related to both physical and
mental HRQoL, in the AYA PWH and VWD popula-
tions. Previous research has suggested that better adher-
ence to prescribed treatment regimens is associated with
less chronic pain [25]. Future research should explore
(1) why women had lower physical HRQoL scores—even
after adjustment for other sociodemographic and clinical
factors, and (2) how prophylaxis may improve overall
mental/emotional HRQoL in the AYA PWH and VWD
populations.
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